

# Miriam Molina-Arcas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6308442/publications.pdf>

Version: 2024-02-01

31  
papers

2,685  
citations

279798

23  
h-index

434195

31  
g-index

33  
all docs

33  
docs citations

33  
times ranked

5385  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. <i>Epilepsy and Behavior</i> , 2021, 115, 107602.	1.7	11
2	Drugging the Undruggable: Advances on RAS Targeting in Cancer. <i>Genes</i> , 2021, 12, 899.	2.4	44
3	Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	19
4	Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. <i>Nature Communications</i> , 2021, 12, 5906.	12.8	36
5	Scalable and robust SARS-CoV-2 testing in an academic center. <i>Nature Biotechnology</i> , 2020, 38, 927-931.	17.5	32
6	Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. <i>Lancet</i> , The, 2020, 396, e6-e7.	13.7	196
7	IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche. <i>Nature Communications</i> , 2020, 11, 764.	12.8	41
8	RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. <i>Cancer Cell</i> , 2019, 36, 68-83.e9.	16.8	104
9	Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	150
10	SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. <i>Nature Communications</i> , 2019, 10, 2532.	12.8	53
11	Oncogenic RAS Signaling Promotes Tumor Immuno-resistance by Stabilizing PD-L1 mRNA. <i>Immunity</i> , 2017, 47, 1083-1099.e6.	14.3	450
12	RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. <i>Nature Communications</i> , 2016, 7, 11245.	12.8	52
13	Hypoxia and P1 receptor activation regulate the high-affinity concentrative adenosine transporter CNT2 in differentiated neuronal PC12 cells. <i>Biochemical Journal</i> , 2013, 454, 437-445.	3.7	26
14	Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 548-563.	9.4	153
15	Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. <i>Cell Research</i> , 2012, 22, 1227-1245.	12.0	155
16	The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer. <i>Cell</i> , 2012, 149, 642-655.	28.9	247
17	Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs. <i>BMC Cancer</i> , 2012, 12, 434.	2.6	28
18	How to Fool a Wonder Drug: Truncate and Dimerize. <i>Cancer Cell</i> , 2012, 21, 7-9.	16.8	5

#	ARTICLE	IF	CITATIONS
19	The Human Concentrative Nucleoside Transporter-3 C602R Variant Shows Impaired Sorting to Lipid Rafts and Altered Specificity for Nucleoside-Derived Drugs. <i>Molecular Pharmacology</i> , 2010, 78, 157-165.	2.3	19
20	A splice variant of the <i>SLC28A3</i> gene encodes a novel human concentrative nucleoside transporter (hCNT3) protein localized in the endoplasmic reticulum. <i>FASEB Journal</i> , 2009, 23, 172-182.	0.5	42
21	Transport of Lamivudine [(-)-2',3'-Dideoxy-3-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 252-261.	2.5	125
22	Nucleoside Transporter Proteins. <i>Current Vascular Pharmacology</i> , 2009, 7, 426-434.	1.7	135
23	Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells. <i>Biochemical Pharmacology</i> , 2008, 75, 639-648.	4.4	23
24	Physiological and Pharmacological Roles of Nucleoside Transporter Proteins. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2008, 27, 769-778.	1.1	40
25	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2008, 93, 1843-1851.	3.5	20
26	Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 558-567.	2.5	66
27	Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells. <i>Biochemical Pharmacology</i> , 2006, 72, 1646-1656.	4.4	27
28	3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. <i>Antiviral Therapy</i> , 2006, 11, 803-11.	1.0	7
29	Cell entry and export of nucleoside analogues. <i>Virus Research</i> , 2005, 107, 151-164.	2.2	127
30	Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2003, 101, 2328-2334.	1.4	101
31	Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. <i>Clinical Cancer Research</i> , 2003, 9, 5000-8.	7.0	144